Device Authority targets enterprise IoT security demand through Xalient partnership

Tern plc

Device Authority has partnered with Xalient to strengthen IoT security for enterprise customers, with its KeyScaler platform being added to Xalient’s managed cybersecurity services.

The partnership is designed to help large organisations secure connected devices more effectively, particularly where IoT and operational technology assets are spread across complex environments. Device Authority is being positioned inside a managed enterprise security offering, giving it a clearer route to customers that need scalable device identity and access management.

Xalient provides identity-led cybersecurity and managed security services. By integrating Device Authority’s KeyScaler technology, it will be able to offer automated protection for connected devices across their full lifecycle. This includes device onboarding, credential management, certificate rotation, access control and decommissioning.

These are practical security functions for enterprises. As more organisations connect equipment, sensors, machines and operational systems, the number of devices that need to be identified, authenticated and managed continues to grow. Manual processes are difficult to scale and can increase risk. Automated device identity management helps reduce gaps in visibility and control.

The partnership focuses on sectors where secure connected infrastructure matters. Energy and utilities, manufacturing, healthcare and critical infrastructure often run large device networks where downtime, unauthorised access or weak credential management can create operational and compliance risks.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search